Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
|
02 October 2019 |
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
|
05 September 2019 |
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
|
16 July 2019 |
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
|
11 July 2019 |
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
|
01 July 2019 |
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
|
06 June 2019 |
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
|
03 June 2019 |
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
|
22 May 2019 |
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
|
14 May 2019 |
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians
|
07 May 2019 |
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
|
09 April 2019 |
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
|
03 April 2019 |
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
|
01 April 2019 |
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
|
27 March 2019 |
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
|
15 March 2019 |
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
|
11 March 2019 |
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
|
04 March 2019 |
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
|
18 February 2019 |
Sandoz and Pear Therapeutics announce US launch of reSET-OTM to help treat Opioid Use Disorder
|
07 January 2019 |
Novartis receives European Commission approval for self-administration of Xolair® across all indications
|
13 December 2018 |